Abstract
Resectable NSCLC with neoadjuvant chemotherapy(CT) has favourable outcomes. However, with few neoadjuvant immunotherapy trials, detailed information on patients(pts) with resectable stage IIIA and IIIB(T3N2) NSCLC is available. Camrelizumab(Cam), a PD-1 antibody, has shown a survival benefit in patients with advanced NSCLC. However, the antitumor activity and safety of Cam plus CT in the neoadjuvant setting is unknown. Here, we report the final analysis from this multi-center, open-label, randomized controlled phase II trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have